Highlights

• FY26 Revenue increased 13% to $10.867bn; underlying EBITDA rose 11% to $1.933bn

• Underlying NPAT increased 17% to $621m; statutory NPAT was $608m, up 18%

• Underlying EPS rose 14% to 125.6 cents; company achieved its FY26 Earnings guidance

• Growth driven by strong revenue growth, Operating Leverage and ongoing Acquisition synergy realisation

Sonic Healthcare Limited (ASX:SHL) is one of the world's largest pathology and radiology groups, operating laboratory networks across Australia, Germany, the USA, Switzerland, the UK, Belgium, Ireland, New Zealand and Canada. The company provides medical testing services to doctors, hospitals and healthcare systems, covering the full range of diagnostic pathology testing — from routine blood tests to complex molecular and genomic testing. Sonic has built its global network through a combination of organic growth and strategic acquisitions, creating Economies of Scale in laboratory operations while maintaining a federated management model that preserves local expertise and relationships.

Latest Developments

Sonic Healthcare produced a strong FY26 result. Revenue increased 13% to $10.867bn, underlying EBITDA rose 11% to $1.933bn, and underlying NPAT increased 17% to $621m. Statutory NPAT was $608m, up 18%, while underlying EPS rose 14% to 125.6c. The company said the result reflected strong revenue growth, operating leverage and ongoing synergy realisation, and importantly it achieved its earnings guidance. Sonic therefore enters FY27 with a stronger earnings base and continued benefits from its international laboratory operations.

Industry Context

Global pathology and diagnostic laboratory markets are experiencing structural growth driven by ageing populations, increasing chronic disease prevalence, expanding genomic and molecular testing capabilities and a growing emphasis on preventive healthcare. The laboratory sector benefits from significant barriers to entry — medical relationships, regulatory accreditations, geographic network density and Capital Investment in laboratory automation — that make scale operations highly defensible. Germany, the USA and Australia remain Sonic's three largest markets, and the recovery of routine testing volumes post-pandemic has been a key earnings driver, combined with the structural Volume growth in preventive and specialised testing.

Key Risks

• Currency risk: Sonic earns a significant proportion of revenue in EUR, USD and other non-AUD currencies that can impact reported results

• Government fee-setting pressure in pathology, particularly Medicare rebates in Australia and statutory pricing in Germany

• Integration risk from ongoing acquisitions if purchase prices are elevated or synergies take longer to realise

• Competitive pressure in key markets from other large laboratory groups (Quest, Labcorp in US; Cerba in Europe)

• Labour cost Inflation in laboratory operations — skilled scientists and technicians are in high Demand globally

Key Catalysts to Watch

• FY27 earnings growth continuing above the underlying NPAT 17% FY26 trajectory through volume growth and Margin leverage

• New acquisitions in European or US markets adding geographic density and synergy opportunities

• Molecular and genomic testing volume growth driving a premium mix-shift within the testing revenue base

• Currency tailwinds if the Australian dollar weakens against EUR and USD, boosting reported AUD earnings

• AI-driven laboratory automation reducing per-test costs and improving throughput at scale

Conclusion

Sonic Healthcare (ASX:SHL) has delivered one of the strongest results in this ASX group, with 13% revenue growth and 17% underlying NPAT growth demonstrating the power of its global laboratory scale model. Achieving earnings guidance in a period of ongoing macro uncertainty is a mark of management quality. For long-term healthcare investors, Sonic represents a genuinely defensive growth compounder: a globally diversified healthcare essential services Business with multiple levers for continued earnings growth. FY27 enters with strong momentum and an improving earnings base.